Vaxart

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Earnings data Q2 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

The stock price of Vaxart Inc (NASDAQ: VXRT) increased by over 10% pre-market. This is why it happened.

VXRT Stock Increases Over 10% Pre-Market: Why It Happened

SOUTH SAN FRANCISCO, Calif., July 29, 2021 /PRNewswire/ -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has shown for the first time in clinical trials that its oral tablet vaccine platform successfully boosted immune responses in subjects previously vaccinated with a Vaxart oral vaccine more than a year earlier.

Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine

On Vaxart's (VXRT) second-quarter earnings call, investors are set to mainly focus on updates on the company's progress with oral vaccine candidates for COVID-19 and Norovirus.

Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?

You can buy VXRT stock for the company's tablet-based Covid-19 vaccine, and hold it for Vaxart's other clinical breakthroughs. The post Vaxart Stock Has Built-In Value Well Beyond Its Covid Pill appeared first on InvestorPlace.

Vaxart Stock Has Built-In Value Well Beyond Its Covid Pill

On July 22, both The Jerusalem Post and Forbes reported that Oravax Medical's oral COVID vaccine candidate is about to begin a phase 1 trial in Israel. While Israel is said to be "first in world" to test "Oravax" oral COVID vaccine, Vaxart, a US-based company, has completed a phase 1 trial of their oral COVID vaccine.

Vaxart: World's First Oral COVID Vaccine In Development

Vaxart may have a second chance at prominence with its Covid-19 vaccine pill. But VXRT stock is still a largely speculative buy.

Vaxart Is Gaining Relevance, But Its Future Is Still Uncertain

The first half has been a cycle of hope and disappointment for shareholders.

Why Shares of Vaxart Jumped 31.2% in the First Half of 2021

BioNTech SE

Co-Diagnostics

Moderna

Novavax

Pfizer

The surge in cases and deaths could significantly ramp up demand for these companies' existing and pipeline products.

Why Coronavirus Stocks Are Zooming Higher Today

Inovio Pharmaceuticals

Analysts' high-water price targets imply some serious gains for these companies.

3 Small-Cap Stocks With 158% to 329% Upside, According to Wall Street

VXRT stock remains a speculative bet as the company's chance to develop an oral Covid-19 vaccine grows slimmer every day. The post Don't Count on a Covid-19 Boost for Vaxart appeared first on InvestorPlace.

Don't Count on a Covid-19 Boost for Vaxart

Duluth Hlds

Lovesac Company

With the summer of recovery under way, these growth stocks could be your best bet.

3 Small-Cap Stocks to Buy in July

Vaxart recently made a licensing deal, and two research firms issued upbeat assessments of the company, making me more upbeat on VXRT stock. The post New Developments Have Made Vaxart Stock So Much More Attractive appeared first on InvestorPlace.

New Developments Have Made Vaxart Stock So Much More Attractive

Vaxart needs a Covid-19 vaccine approved and selling on the market before the established mega-cap names take all the sales. The post Watch Out for a Selloff in Vaxart Stock appeared first on InvestorPlace.

Watch Out for a Selloff in Vaxart Stock

Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.

Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral

The stock price of Vaxart Inc (NASDAQ: VXRT) fell by 3.8%. This is why it happened.

Vaxart Stock Fell 3.8%: Why It Happened

Vaxart Inc (NASDAQ: VXRT) has granted Altesa Biosciences Inc an exclusive worldwide license to develop and commercialize Vaxart's patented formulation of the capsid-binding Vapendavir, a clinical-stage broad-spectrum antiviral. Under the terms of the agreement, Vaxart is eligible to receive up to $130 million in milestone payments and tiered royalties ranging from the low-single to low-double digits on product sales for multiple indications.

Vaxart Inks Antiviral Asset Licensing Pact With Altesa Biosciences

Milestone payments up to $130 million and royalties for global Vapendavir sales

Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset

VXRT stock is known to be a fast mover. Any piece of good news could prove to be a multi-bagger for investors who take an early position.

Vaxart Stock Could Make Another Big Return in the Future

VXRT stock just received a buy recommendation and a $13 price target from Jefferies, based on the promise of a oral vaccine instead of a needle. The post Will the Promise of Avoiding the Needle Pay Off for Vaxart?

Will the Promise of Avoiding the Needle Pay Off for Vaxart?

Coty

Kinross Gold

QUALCOMM

Shift Technologies

While most of Wall Street focuses on large and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Sizzling Stocks To Buy Now Trading Under $10 With Massive Upside Potential

Today, VXRT stock is climbing higher on an otherwise red day for the markets, as many speculate retail investors could be behind this rise. The post VXRT Stock: Can Redditors Help Vaxart Power Higher?

VXRT Stock: Can Redditors Help Vaxart Power Higher?

Vaxart is still not worth today's price. VXRT stock is worth no more than $6, especially if it's going to need another capital raise.

Vaxart Is Still Not Worth Anywhere Near Its Present Price

Investors need to pay close attention to Vaxart (VXRT) stock based on the movements in the options market lately.

Implied Volatility Surging for Vaxart (VXRT) Stock Options

Dynavax Technologies

The declines appear to be caused simply by volatility that's common with small biotech stocks.

Why COVID Vaccine Stocks Dynavax, Novavax, and Vaxart Are Sinking Today

The stock price of Vaxart Inc (NASDAQ: VXRT) increased by 21.9% yesterday. This is why it happened.

News for Vaxart Stock (VXRT)